Renal tumors: Diagnostic and prognostic biomarkers

Puay Hoon Tan; Liang Cheng; Nathalie Rioux-Leclercq; Maria J. Merino; Georges J Netto; Victor E. Reuter; Steven S. Shen; David J. Grignon; Rodolfo Montironi; Lars Egevad; John R. Srigley; Brett Delahunt; Holger Moch; Anila Abraham; Adebowale Adeniran; Khalid Ahmed; Hikmat Al Ahmadie; Ferran Algaba; Robert Allan; Mahul Amin; Pedram Argani; Ulrika Axcrona; Marc Barry; Dilek Baydar; Louis Bégin; Dan Berney; Peter Bethwaite; Athanase Billis; Ruth Birbe; Stephen Bonsib; David Bostwick; Fadi Brimo; Helen Cathro; Ying Bei Chen; John Cheville; Yong Mee Cho; Ai Ying Chuang; Cynthia Cohen; Henry Crist; Warick Delprado; Fang Ming Deng; Jonathan Epstein; Andrew Evans; Oluwole Fadare; Daniel Fajardo; Sara Falzarano; Samson Fine; Stewart Fleming; Eddie Fridman; Bungo Furusato; Masoud Ganji; Masoumeh Ghayouri; Giovanna Giannico; Neriman Gokden; David Griffiths; Nilesh Gupta; Omar Hameed; Ondrej Hes; Michelle Hirsch; Jiaoti Huang; Wei Huang; Christina Hulsbergen Van De Kaa; Peter Humphrey; Sundus Hussein; Kenneth Iczkowski; Rafael Jimenez; Edward Jones; Laura Irene Jufe; James Kench; Masatoshi Kida; Glen Kristiansen; Lakshmi Priya Kunju; Zhaoli Lane; Mathieu Latour; Claudio Lewin; Kathrine Lie; Josep Lloreta; Barbara Loftus; Antonio Lopez-Beltran; Fiona Maclean; Cristina Magi-Galluzzi; Guido Martignoni; Teresa McHale; Jesse McKenney; Rose Miller; Hiroshi Miyamoto; Hedwig Murphy; John Nacey; Tipu Nazeer; Gabriella Nesi; Peter Nichols; Marie O'Donnell; Semra Olgac; Roberto Orozco; Adeboye Osunkoya; Aysim Ozagari; Chin Chen Pan; Anil Parwani; Joanna Perry-Keene; Constantina Petraki; Maria Picken; Maria Pyda-Karwicka; Katayoon Rezaei; Brian Robinson; Stephen Rohan; Ruben Ronchetti; Laurie Russell; Hemamali Samaratunga; Marina Scarpelli; Ahmed Shabaik; Rajal Shah; Jonathan Shanks; Maria Shevchuk; Mathilde Sibony; Bhuvana Srinivasan; Martin Susani; Sueli Suzigan; Joan Sweet; Hiroyuki Takahashi; Pheroze Tamboli; Satish Tickoo; Isabel Trias; Kiril Trpkov; Larry True; Toyonori Tsuzuki; Funda Vakar-Lopez; Theo Van Der Kwast; Cheng Wang; Anne Warren; Jorge Yao; Asli Yilmaz; Jin Zhao; Ming Zhou; Debra Zynger

doi:10.1097/PAS.0b013e318299f12e

Renal tumors: Diagnostic and prognostic biomarkers

Puay Hoon Tan, Liang Cheng, Nathalie Rioux-Leclercq, Maria J. Merino, Georges J Netto, Victor E. Reuter, Steven S. Shen, David J. Grignon, Rodolfo Montironi, Lars Egevad, John R. Srigley, Brett Delahunt, Holger Moch, Anila Abraham, Adebowale Adeniran, Khalid Ahmed, Hikmat Al Ahmadie, Ferran Algaba, Robert Allan, Mahul AminPedram Argani, Ulrika Axcrona, Marc Barry, Dilek Baydar, Louis Bégin, Dan Berney, Peter Bethwaite, Athanase Billis, Ruth Birbe, Stephen Bonsib, David Bostwick, Fadi Brimo, Helen Cathro, Ying Bei Chen, John Cheville, Yong Mee Cho, Ai Ying Chuang, Cynthia Cohen, Henry Crist, Warick Delprado, Fang Ming Deng, Jonathan Epstein, Andrew Evans, Oluwole Fadare, Daniel Fajardo, Sara Falzarano, Samson Fine, Stewart Fleming, Eddie Fridman, Bungo Furusato, Masoud Ganji, Masoumeh Ghayouri, Giovanna Giannico, Neriman Gokden, David Griffiths, Nilesh Gupta, Omar Hameed, Ondrej Hes, Michelle Hirsch, Jiaoti Huang, Wei Huang, Christina Hulsbergen Van De Kaa, Peter Humphrey, Sundus Hussein, Kenneth Iczkowski, Rafael Jimenez, Edward Jones, Laura Irene Jufe, James Kench, Masatoshi Kida, Glen Kristiansen, Lakshmi Priya Kunju, Zhaoli Lane, Mathieu Latour, Claudio Lewin, Kathrine Lie, Josep Lloreta, Barbara Loftus, Antonio Lopez-Beltran, Fiona Maclean, Cristina Magi-Galluzzi, Guido Martignoni, Teresa McHale, Jesse McKenney, Rose Miller, Hiroshi Miyamoto, Hedwig Murphy, John Nacey, Tipu Nazeer, Gabriella Nesi, Peter Nichols, Marie O'Donnell, Semra Olgac, Roberto Orozco, Adeboye Osunkoya, Aysim Ozagari, Chin Chen Pan, Anil Parwani, Joanna Perry-Keene, Constantina Petraki, Maria Picken, Maria Pyda-Karwicka, Katayoon Rezaei, Brian Robinson, Stephen Rohan, Ruben Ronchetti, Laurie Russell, Hemamali Samaratunga, Marina Scarpelli, Ahmed Shabaik, Rajal Shah, Jonathan Shanks, Maria Shevchuk, Mathilde Sibony, Bhuvana Srinivasan, Martin Susani, Sueli Suzigan, Joan Sweet, Hiroyuki Takahashi, Pheroze Tamboli, Satish Tickoo, Isabel Trias, Kiril Trpkov, Larry True, Toyonori Tsuzuki, Funda Vakar-Lopez, Theo Van Der Kwast, Cheng Wang, Anne Warren, Jorge Yao, Asli Yilmaz, Jin Zhao, Ming Zhou, Debra Zynger

School of Medicine

Research output: Contribution to journal › Article › peer-review

113 Scopus citations

Abstract

The International Society of Urological Pathology convened a consensus conference on renal cancer, preceded by an online survey, to address issues relating to the diagnosis and reporting of renal neoplasia. In this report, the role of biomarkers in the diagnosis and assessment of prognosis of renal tumors is addressed. In particular we focused upon the use of immunohistochemical markers and the approach to specific differential diagnostic scenarios. We enquired whether cytogenetic and molecular tools were applied in practice and asked for views on the perceived prognostic role of biomarkers. Both the survey and conference voting results demonstrated a high degree of consensus in participants' responses regarding prognostic/ predictive markers and molecular techniques, whereas it was apparent that biomarkers for these purposes remained outside the diagnostic realm pending clinical validation. Although no individual antibody or panel of antibodies reached consensus for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the online survey that 87% of respondents used immunohistochemistry to subtype renal tumors sometimes or occasionally, and a majority (87%) used immunohistochemical markers (Pax 2 or Pax 8, renal cell carcinoma [RCC] marker, panel of pan-CK, CK7, vimentin, and CD10) in confirming the diagnosis of metastatic RCC. There was consensus that immunohistochemistry should be used for histologic subtyping and applied before reaching a diagnosis of unclassified RCC. At the conference, there was consensus that TFE3 and TFEB analysis ought to be requested when RCC was diagnosed in a young patient or when histologic appearances were suggestive of the translocation subtype; whereas Pax 2 and/ or Pax 8 were considered to be the most useful markers in the diagnosis of a renal primary.

Original language	English (US)
Pages (from-to)	1518-1531
Number of pages	14
Journal	American Journal of Surgical Pathology
Volume	37
Issue number	10
DOIs	https://doi.org/10.1097/PAS.0b013e318299f12e
State	Published - Oct 2013

Keywords

CK7
Immunohistochemistry
International Society of Urological Pathology
Pax 2
Pax 8
Renal cell carcinoma
Translocation carcinoma

ASJC Scopus subject areas

Anatomy
Surgery
Pathology and Forensic Medicine

Access to Document

10.1097/PAS.0b013e318299f12e

Cite this

Tan, P. H., Cheng, L., Rioux-Leclercq, N., Merino, M. J., Netto, G. J., Reuter, V. E., Shen, S. S., Grignon, D. J., Montironi, R., Egevad, L., Srigley, J. R., Delahunt, B., Moch, H., Abraham, A., Adeniran, A., Ahmed, K., Al Ahmadie, H., Algaba, F., Allan, R., ... Zynger, D. (2013). Renal tumors: Diagnostic and prognostic biomarkers. American Journal of Surgical Pathology, 37(10), 1518-1531. https://doi.org/10.1097/PAS.0b013e318299f12e

Tan, PH, Cheng, L, Rioux-Leclercq, N, Merino, MJ, Netto, GJ, Reuter, VE, Shen, SS, Grignon, DJ, Montironi, R, Egevad, L, Srigley, JR, Delahunt, B, Moch, H, Abraham, A, Adeniran, A, Ahmed, K, Al Ahmadie, H, Algaba, F, Allan, R, Amin, M, Argani, P, Axcrona, U, Barry, M, Baydar, D, Bégin, L, Berney, D, Bethwaite, P, Billis, A, Birbe, R, Bonsib, S, Bostwick, D, Brimo, F, Cathro, H, Chen, YB, Cheville, J, Cho, YM, Chuang, AY, Cohen, C, Crist, H, Delprado, W, Deng, FM, Epstein, J, Evans, A, Fadare, O, Fajardo, D, Falzarano, S, Fine, S, Fleming, S, Fridman, E, Furusato, B, Ganji, M, Ghayouri, M, Giannico, G, Gokden, N, Griffiths, D, Gupta, N, Hameed, O, Hes, O, Hirsch, M, Huang, J, Huang, W, Van De Kaa, CH, Humphrey, P, Hussein, S, Iczkowski, K, Jimenez, R, Jones, E, Jufe, LI, Kench, J, Kida, M, Kristiansen, G, Kunju, LP, Lane, Z, Latour, M, Lewin, C, Lie, K, Lloreta, J, Loftus, B, Lopez-Beltran, A, Maclean, F, Magi-Galluzzi, C, Martignoni, G, McHale, T, McKenney, J, Miller, R, Miyamoto, H, Murphy, H, Nacey, J, Nazeer, T, Nesi, G, Nichols, P, O'Donnell, M, Olgac, S, Orozco, R, Osunkoya, A, Ozagari, A, Pan, CC, Parwani, A, Perry-Keene, J, Petraki, C, Picken, M, Pyda-Karwicka, M, Rezaei, K, Robinson, B, Rohan, S, Ronchetti, R, Russell, L, Samaratunga, H, Scarpelli, M, Shabaik, A, Shah, R, Shanks, J, Shevchuk, M, Sibony, M, Srinivasan, B, Susani, M, Suzigan, S, Sweet, J, Takahashi, H, Tamboli, P, Tickoo, S, Trias, I, Trpkov, K, True, L, Tsuzuki, T, Vakar-Lopez, F, Van Der Kwast, T, Wang, C, Warren, A, Yao, J, Yilmaz, A, Zhao, J, Zhou, M & Zynger, D 2013, 'Renal tumors: Diagnostic and prognostic biomarkers', American Journal of Surgical Pathology, vol. 37, no. 10, pp. 1518-1531. https://doi.org/10.1097/PAS.0b013e318299f12e

@article{29631b01f44b46b38eb5db77592b9bb6,

title = "Renal tumors: Diagnostic and prognostic biomarkers",

abstract = "The International Society of Urological Pathology convened a consensus conference on renal cancer, preceded by an online survey, to address issues relating to the diagnosis and reporting of renal neoplasia. In this report, the role of biomarkers in the diagnosis and assessment of prognosis of renal tumors is addressed. In particular we focused upon the use of immunohistochemical markers and the approach to specific differential diagnostic scenarios. We enquired whether cytogenetic and molecular tools were applied in practice and asked for views on the perceived prognostic role of biomarkers. Both the survey and conference voting results demonstrated a high degree of consensus in participants' responses regarding prognostic/ predictive markers and molecular techniques, whereas it was apparent that biomarkers for these purposes remained outside the diagnostic realm pending clinical validation. Although no individual antibody or panel of antibodies reached consensus for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the online survey that 87% of respondents used immunohistochemistry to subtype renal tumors sometimes or occasionally, and a majority (87%) used immunohistochemical markers (Pax 2 or Pax 8, renal cell carcinoma [RCC] marker, panel of pan-CK, CK7, vimentin, and CD10) in confirming the diagnosis of metastatic RCC. There was consensus that immunohistochemistry should be used for histologic subtyping and applied before reaching a diagnosis of unclassified RCC. At the conference, there was consensus that TFE3 and TFEB analysis ought to be requested when RCC was diagnosed in a young patient or when histologic appearances were suggestive of the translocation subtype; whereas Pax 2 and/ or Pax 8 were considered to be the most useful markers in the diagnosis of a renal primary.",

keywords = "CK7, Immunohistochemistry, International Society of Urological Pathology, Pax 2, Pax 8, Renal cell carcinoma, Translocation carcinoma",

author = "Tan, {Puay Hoon} and Liang Cheng and Nathalie Rioux-Leclercq and Merino, {Maria J.} and Netto, {Georges J} and Reuter, {Victor E.} and Shen, {Steven S.} and Grignon, {David J.} and Rodolfo Montironi and Lars Egevad and Srigley, {John R.} and Brett Delahunt and Holger Moch and Anila Abraham and Adebowale Adeniran and Khalid Ahmed and {Al Ahmadie}, Hikmat and Ferran Algaba and Robert Allan and Mahul Amin and Pedram Argani and Ulrika Axcrona and Marc Barry and Dilek Baydar and Louis B{\'e}gin and Dan Berney and Peter Bethwaite and Athanase Billis and Ruth Birbe and Stephen Bonsib and David Bostwick and Fadi Brimo and Helen Cathro and Chen, {Ying Bei} and John Cheville and Cho, {Yong Mee} and Chuang, {Ai Ying} and Cynthia Cohen and Henry Crist and Warick Delprado and Deng, {Fang Ming} and Jonathan Epstein and Andrew Evans and Oluwole Fadare and Daniel Fajardo and Sara Falzarano and Samson Fine and Stewart Fleming and Eddie Fridman and Bungo Furusato and Masoud Ganji and Masoumeh Ghayouri and Giovanna Giannico and Neriman Gokden and David Griffiths and Nilesh Gupta and Omar Hameed and Ondrej Hes and Michelle Hirsch and Jiaoti Huang and Wei Huang and {Van De Kaa}, {Christina Hulsbergen} and Peter Humphrey and Sundus Hussein and Kenneth Iczkowski and Rafael Jimenez and Edward Jones and Jufe, {Laura Irene} and James Kench and Masatoshi Kida and Glen Kristiansen and Kunju, {Lakshmi Priya} and Zhaoli Lane and Mathieu Latour and Claudio Lewin and Kathrine Lie and Josep Lloreta and Barbara Loftus and Antonio Lopez-Beltran and Fiona Maclean and Cristina Magi-Galluzzi and Guido Martignoni and Teresa McHale and Jesse McKenney and Rose Miller and Hiroshi Miyamoto and Hedwig Murphy and John Nacey and Tipu Nazeer and Gabriella Nesi and Peter Nichols and Marie O'Donnell and Semra Olgac and Roberto Orozco and Adeboye Osunkoya and Aysim Ozagari and Pan, {Chin Chen} and Anil Parwani and Joanna Perry-Keene and Constantina Petraki and Maria Picken and Maria Pyda-Karwicka and Katayoon Rezaei and Brian Robinson and Stephen Rohan and Ruben Ronchetti and Laurie Russell and Hemamali Samaratunga and Marina Scarpelli and Ahmed Shabaik and Rajal Shah and Jonathan Shanks and Maria Shevchuk and Mathilde Sibony and Bhuvana Srinivasan and Martin Susani and Sueli Suzigan and Joan Sweet and Hiroyuki Takahashi and Pheroze Tamboli and Satish Tickoo and Isabel Trias and Kiril Trpkov and Larry True and Toyonori Tsuzuki and Funda Vakar-Lopez and {Van Der Kwast}, Theo and Cheng Wang and Anne Warren and Jorge Yao and Asli Yilmaz and Jin Zhao and Ming Zhou and Debra Zynger",

year = "2013",

month = oct,

doi = "10.1097/PAS.0b013e318299f12e",

language = "English (US)",

volume = "37",

pages = "1518--1531",

journal = "American Journal of Surgical Pathology",

issn = "0147-5185",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Renal tumors

T2 - Diagnostic and prognostic biomarkers

AU - Tan, Puay Hoon

AU - Cheng, Liang

AU - Rioux-Leclercq, Nathalie

AU - Merino, Maria J.

AU - Netto, Georges J

AU - Reuter, Victor E.

AU - Shen, Steven S.

AU - Grignon, David J.

AU - Montironi, Rodolfo

AU - Egevad, Lars

AU - Srigley, John R.

AU - Delahunt, Brett

AU - Moch, Holger

AU - Abraham, Anila

AU - Adeniran, Adebowale

AU - Ahmed, Khalid

AU - Al Ahmadie, Hikmat

AU - Algaba, Ferran

AU - Allan, Robert

AU - Amin, Mahul

AU - Argani, Pedram

AU - Axcrona, Ulrika

AU - Barry, Marc

AU - Baydar, Dilek

AU - Bégin, Louis

AU - Berney, Dan

AU - Bethwaite, Peter

AU - Billis, Athanase

AU - Birbe, Ruth

AU - Bonsib, Stephen

AU - Bostwick, David

AU - Brimo, Fadi

AU - Cathro, Helen

AU - Chen, Ying Bei

AU - Cheville, John

AU - Cho, Yong Mee

AU - Chuang, Ai Ying

AU - Cohen, Cynthia

AU - Crist, Henry

AU - Delprado, Warick

AU - Deng, Fang Ming

AU - Epstein, Jonathan

AU - Evans, Andrew

AU - Fadare, Oluwole

AU - Fajardo, Daniel

AU - Falzarano, Sara

AU - Fine, Samson

AU - Fleming, Stewart

AU - Fridman, Eddie

AU - Furusato, Bungo

AU - Ganji, Masoud

AU - Ghayouri, Masoumeh

AU - Giannico, Giovanna

AU - Gokden, Neriman

AU - Griffiths, David

AU - Gupta, Nilesh

AU - Hameed, Omar

AU - Hes, Ondrej

AU - Hirsch, Michelle

AU - Huang, Jiaoti

AU - Huang, Wei

AU - Van De Kaa, Christina Hulsbergen

AU - Humphrey, Peter

AU - Hussein, Sundus

AU - Iczkowski, Kenneth

AU - Jimenez, Rafael

AU - Jones, Edward

AU - Jufe, Laura Irene

AU - Kench, James

AU - Kida, Masatoshi

AU - Kristiansen, Glen

AU - Kunju, Lakshmi Priya

AU - Lane, Zhaoli

AU - Latour, Mathieu

AU - Lewin, Claudio

AU - Lie, Kathrine

AU - Lloreta, Josep

AU - Loftus, Barbara

AU - Lopez-Beltran, Antonio

AU - Maclean, Fiona

AU - Magi-Galluzzi, Cristina

AU - Martignoni, Guido

AU - McHale, Teresa

AU - McKenney, Jesse

AU - Miller, Rose

AU - Miyamoto, Hiroshi

AU - Murphy, Hedwig

AU - Nacey, John

AU - Nazeer, Tipu

AU - Nesi, Gabriella

AU - Nichols, Peter

AU - O'Donnell, Marie

AU - Olgac, Semra

AU - Orozco, Roberto

AU - Osunkoya, Adeboye

AU - Ozagari, Aysim

AU - Pan, Chin Chen

AU - Parwani, Anil

AU - Perry-Keene, Joanna

AU - Petraki, Constantina

AU - Picken, Maria

AU - Pyda-Karwicka, Maria

AU - Rezaei, Katayoon

AU - Robinson, Brian

AU - Rohan, Stephen

AU - Ronchetti, Ruben

AU - Russell, Laurie

AU - Samaratunga, Hemamali

AU - Scarpelli, Marina

AU - Shabaik, Ahmed

AU - Shah, Rajal

AU - Shanks, Jonathan

AU - Shevchuk, Maria

AU - Sibony, Mathilde

AU - Srinivasan, Bhuvana

AU - Susani, Martin

AU - Suzigan, Sueli

AU - Sweet, Joan

AU - Takahashi, Hiroyuki

AU - Tamboli, Pheroze

AU - Tickoo, Satish

AU - Trias, Isabel

AU - Trpkov, Kiril

AU - True, Larry

AU - Tsuzuki, Toyonori

AU - Vakar-Lopez, Funda

AU - Van Der Kwast, Theo

AU - Wang, Cheng

AU - Warren, Anne

AU - Yao, Jorge

AU - Yilmaz, Asli

AU - Zhao, Jin

AU - Zhou, Ming

AU - Zynger, Debra

PY - 2013/10

Y1 - 2013/10

N2 - The International Society of Urological Pathology convened a consensus conference on renal cancer, preceded by an online survey, to address issues relating to the diagnosis and reporting of renal neoplasia. In this report, the role of biomarkers in the diagnosis and assessment of prognosis of renal tumors is addressed. In particular we focused upon the use of immunohistochemical markers and the approach to specific differential diagnostic scenarios. We enquired whether cytogenetic and molecular tools were applied in practice and asked for views on the perceived prognostic role of biomarkers. Both the survey and conference voting results demonstrated a high degree of consensus in participants' responses regarding prognostic/ predictive markers and molecular techniques, whereas it was apparent that biomarkers for these purposes remained outside the diagnostic realm pending clinical validation. Although no individual antibody or panel of antibodies reached consensus for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the online survey that 87% of respondents used immunohistochemistry to subtype renal tumors sometimes or occasionally, and a majority (87%) used immunohistochemical markers (Pax 2 or Pax 8, renal cell carcinoma [RCC] marker, panel of pan-CK, CK7, vimentin, and CD10) in confirming the diagnosis of metastatic RCC. There was consensus that immunohistochemistry should be used for histologic subtyping and applied before reaching a diagnosis of unclassified RCC. At the conference, there was consensus that TFE3 and TFEB analysis ought to be requested when RCC was diagnosed in a young patient or when histologic appearances were suggestive of the translocation subtype; whereas Pax 2 and/ or Pax 8 were considered to be the most useful markers in the diagnosis of a renal primary.

AB - The International Society of Urological Pathology convened a consensus conference on renal cancer, preceded by an online survey, to address issues relating to the diagnosis and reporting of renal neoplasia. In this report, the role of biomarkers in the diagnosis and assessment of prognosis of renal tumors is addressed. In particular we focused upon the use of immunohistochemical markers and the approach to specific differential diagnostic scenarios. We enquired whether cytogenetic and molecular tools were applied in practice and asked for views on the perceived prognostic role of biomarkers. Both the survey and conference voting results demonstrated a high degree of consensus in participants' responses regarding prognostic/ predictive markers and molecular techniques, whereas it was apparent that biomarkers for these purposes remained outside the diagnostic realm pending clinical validation. Although no individual antibody or panel of antibodies reached consensus for classifying renal tumors, or for confirming renal metastatic disease, it was noted from the online survey that 87% of respondents used immunohistochemistry to subtype renal tumors sometimes or occasionally, and a majority (87%) used immunohistochemical markers (Pax 2 or Pax 8, renal cell carcinoma [RCC] marker, panel of pan-CK, CK7, vimentin, and CD10) in confirming the diagnosis of metastatic RCC. There was consensus that immunohistochemistry should be used for histologic subtyping and applied before reaching a diagnosis of unclassified RCC. At the conference, there was consensus that TFE3 and TFEB analysis ought to be requested when RCC was diagnosed in a young patient or when histologic appearances were suggestive of the translocation subtype; whereas Pax 2 and/ or Pax 8 were considered to be the most useful markers in the diagnosis of a renal primary.

KW - CK7

KW - Immunohistochemistry

KW - International Society of Urological Pathology

KW - Pax 2

KW - Pax 8

KW - Renal cell carcinoma

KW - Translocation carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84900393064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900393064&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e318299f12e

DO - 10.1097/PAS.0b013e318299f12e

M3 - Article

C2 - 24025522

AN - SCOPUS:84900393064

SN - 0147-5185

VL - 37

SP - 1518

EP - 1531

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

IS - 10

ER -

Renal tumors: Diagnostic and prognostic biomarkers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this